Source:PIB
Subject: Health, Governance and Regulation of Drugs; Antimicrobial Resistance|Target exams: UPSC
Key points for Prelims: New Drugs and Clinical Trials Rules, 2019, Antimicrobial resistance (AMR), Central Licensing Authority, Bioequivalence and bioavailability studies, G20 New Delhi Leaders' Declaration
Mains syllabus mapping
- General Studies Paper 2: Health; government policies and interventions for development in health sector; regulatory institutions
- General Studies Paper 3: Public health and antimicrobial resistance as a biosecurity and health threat

Key facts for one-day exams
- The antimicrobial amendment was proposed under the New Drugs and Clinical Trials Rules, 2019.
- The draft notification is G.S.R. 983 (E), dated 6 November 2026.
- The proposed definition change concerns Rule 2(1)(w)(v).
- Public objections and suggestions can be submitted within the prescribed 30-day period.
- The G20 New Delhi Leaders’ Declaration highlighted One Health in addressing antimicrobial resistance.
Antimicrobial regulation NDCT Rules 2019: why in the news?
The Ministry of Health and Family Welfare has issued a draft amendment to the New Drugs and Clinical Trials Rules, 2019, proposing central regulatory oversight of antimicrobials. The move is significant because it directly targets the quality and safety of antimicrobial products to combat antimicrobial resistance, a global health priority.
The Union Ministry of Health and Family Welfare has proposed an amendment to the New Drugs and Clinical Trials Rules, 2019, to include antimicrobials in the definition of a new drug under Rule 2(1)(w)(v). The draft notification, G.S.R. 983 (E) dated 6 November, was issued to invite objections and suggestions from stakeholders and the public before the Central Government considers finalising the change. If adopted, the amendment would affect all manufacturers of antimicrobial products in India.
The proposal responds to concerns that manufacturing licences for antimicrobials are being granted without adequate regulatory scrutiny, including bioavailability, bioequivalence and stability studies. The ministry said the absence of such assessments may affect the quality, safety and efficacy of antimicrobial products, and that substandard or ineffective antimicrobials can contribute to the development and spread of antimicrobial resistance, posing risks to patient safety. Under the proposed framework, manufacturers would first need permission from the Central Licensing Authority before applying for a manufacturing licence from the concerned State Licensing Authority. The G20 New Delhi Leaders’ Declaration had also underscored the need to address antimicrobial resistance through a One Health approach.
Key features and how it works
- Defines what counts as a 'new drug' (Rule 2(1)(w)); the draft amendment adds antimicrobials to this definition at sub-clause (v).PIB
- Under the proposal, a two-step licensing route applies: Central Licensing Authority permission first, then the manufacturing licence from the State Licensing Authority.PIB
- The Drugs Controller General of India heads CDSCO and approves clinical trials and new drugs; CDSCO has zonal offices and regulates clinical trials.
- Clinical trials in India must be publicly documented in the Clinical Trials Registry - India, which the Central Drugs Standard Control Organisation has required since 2009 before enrolment.
Related Static GK and comparison
- Central Drugs Standard Control Organisation (CDSCO): responsible for drug approvals, conduct of clinical trials, drug standards and control over the quality of imported drugs.cdsco.gov.in
- Drugs Controller General of India (DCGI): head of CDSCO, responsible for approval of licences for specified categories of drugs, including blood products, IV fluids, vaccines and sera.
- Clinical Trials Registry - India (CTRI): the government's official clinical trial registry, established by the National Institute of Medical Statistics of the Indian Council of Medical Research on 20 July 2007.
- Drugs and Cosmetics Rules, 1945: rules under the Drugs and Cosmetics Act, 1940 that classify drugs into schedules; Schedule Y contains requirements and guidelines for clinical trials.
- Pharmacovigilance Programme of India: tracks reports of harm from the use of drugs.
Achievements
- The draft amendment proposes a central permission step before manufacturers apply for antimicrobial manufacturing licences. The ministry expects this to strengthen central regulatory oversight and help ensure product quality, safety and efficacy.PIB
- The CTRI registration requirement has been reported to help prevent selective reporting of results and duplication of research.
- Trial rules were reformed after the 2013 Supreme Court case Swasthya Adhikar Manch v. Union of India, to make clinical trials more ethical.
Challenges
- In 2015, the government told the Supreme Court that a lack of specific penalties meant it could only halt the HPV vaccine trials and issue warnings.
- Critics say the Indian drug regulator's approval standards are lower than those of the US FDA and the EU's EMA, and that enforcement is weak.
- Registry data quality is a concern, as users register their own trials and the form lacks precision, so errors enter the record.
Way forward
- Finalise the amendment only after the 30-day consultation, with stakeholder objections and suggestions considered by the Central Government.PIB
- Clear penalty provisions for clinical trial violations, which the Drugs and Cosmetics Act currently lacks.
Connected to this news
New Drugs and Clinical Trials Rules, 2019 (proposed amendment to bring antimicrobials under central oversight)
The New Drugs and Clinical Trials Rules, 2019 are India's rules governing new drugs and clinical trials, under which the Health Ministry has proposed (draft of November 2026) to treat antimicrobials as new drugs so that manufacturers need central permission before a state manufacturing licence.
Timeline
19 November 2026This story
Draft amendment proposed to add antimicrobials to the 'new drug' definition under Rule 2(1)(w)(v), requiring central permission before state manufacturing licences, to curb antimicrobial resistance.
6 November 2026
Draft amendment G.S.R. 983 (E) issued proposing antimicrobials be included in the 'new drug' definition under Rule 2(1)(w)(v) of the NDCT Rules, 2019.
15 June 2009
CDSCO makes trial registration mandatory, with pre-registration required before enrolment.
20 July 2007
Clinical Trials Registry - India established by the Indian Council of Medical Research.
1945
Drugs and Cosmetics Rules, 1945 framed under the Act.
1940
Drugs and Cosmetics Act, 1940 passed, originally known as the Drug Act, following the Chopra Committee recommendations.
Key terms
- Antimicrobial resistance:
- Antimicrobial resistance occurs when microorganisms change so that medicines used against them become less effective.
- One Health:
- One Health is an integrated approach recognizing the interdependence of human, animal and environmental health.
- Bioequivalence:
- Bioequivalence describes comparable bioavailability of medicines when administered under appropriate conditions.
- Stability study:
- A stability study examines how a pharmaceutical product's quality changes over time under specified conditions.
Antimicrobial regulation NDCT Rules 2019: why it matters for exams
Exams: UPSC
Syllabus: Science and Technology: Antimicrobial resistance and public health; Governance: Drug regulation and public consultation
Common mistake: Examiners may present the draft amendment as a final rule or a ban on antimicrobials; it is a proposed change to the new-drug regulatory framework.
Mains practice questions
Question 1(GS-2 | 250 words | 15 marks)
Antimicrobial resistance poses a growing threat to public health, and the proposed inclusion of antimicrobials under the New Drugs and Clinical Trials Rules, 2019 seeks to address it. Critically examine the need for central regulatory oversight of antimicrobial manufacturing in India and the challenges it may face.
Answer outline
- Introduction: Open by noting that the Health Ministry's draft amendment (G.S.R. 983 (E), 6 November 2026) would bring antimicrobials under the new drug framework because substandard products can fuel AMR.
- Body:
- Why AMR matters: substandard or ineffective antimicrobials contribute to resistance and endanger patient safety, linking quality control to public health
- Gap being addressed: manufacturing licences granted without bioavailability, bioequivalence and stability studies
- Proposed mechanism: prior permission from the Central Licensing Authority before a State Licensing Authority grants a manufacturing licence
- Federal challenges: possible overlap and delay between central and state authorities, and capacity constraints in state regulators
- Industry and access concerns: compliance costs for small manufacturers and potential effects on availability of affordable antimicrobials
- Conclusion: Central oversight can strengthen quality and AMR control, but its success depends on clear Centre-State coordination, adequate testing infrastructure and a One Health approach as endorsed in the G20 New Delhi Leaders' Declaration.
Question 2(GS-3 | 150 words | 10 marks)
The G20 New Delhi Leaders' Declaration called for a One Health approach to antimicrobial resistance. Discuss how regulatory reforms in drug quality, such as the proposed amendment to the New Drugs and Clinical Trials Rules, 2019, can support this approach.
Answer outline
- Introduction: Link the proposed amendment to the G20 commitment, noting that the draft makes antimicrobial quality a regulatory priority.
- Body:
- One Health meaning: linking human, animal and environmental health in controlling resistance
- Drug quality as a lever: bioequivalence, stability and efficacy testing reduce ineffective dosing that drives resistance
- Preventive regulation: pre-licensing scrutiny by the Central Licensing Authority filters products before they enter the market
- Need for complementary action: surveillance, rational prescribing and veterinary antimicrobial control
- Conclusion: Regulatory reform is a necessary but not sufficient step; it works best when integrated with surveillance and sectoral action under a One Health framework.
Stuck? Get it in one tap
Antimicrobial resistance means microorganisms become less responsive to medicines used against them. The health ministry proposes treating antimicrobials as new drugs for regulatory purposes. Manufacturers would need central permission before seeking a state manufacturing licence; the proposal is still open for feedback.
- Science and Technology: Antimicrobial resistance and public health
- Governance: Drug regulation and public consultation
Related concepts: Antimicrobial resistance, One Health, Bioequivalence, Stability study
Practice questions
Pick an answer, then read the explanation.
- Q1Easy
Which ministry proposed the draft amendment concerning antimicrobials under the New Drugs and Clinical Trials Rules, 2019?
Explanation: The Ministry of Health and Family Welfare proposed the amendment to the drug rules. The other listed ministries are not the proposing ministry.
- Q2Hard
Consider the following statements about the proposed amendment to the New Drugs and Clinical Trials Rules, 2019:
- 1. It proposes including antimicrobials in the definition of a new drug.
- 2. Manufacturers would apply for a state manufacturing licence before seeking central permission.
- 3. The draft invites objections and suggestions before finalisation.
Which of the statements given above are correct?
Explanation: Statements 1 and 3 are correct: the draft proposes new-drug classification and invites public feedback. Statement 2 reverses the proposed sequence: central permission would precede the state licence application.
- Q3Medium
What period is provided for objections and suggestions on the draft antimicrobial amendment after Gazette copies become available to the public?
Explanation: The consultation period is 30 days from the public availability of Gazette copies containing the draft rules. The other periods do not match the draft notification.
- Q4Medium
Why does the draft amendment propose central oversight of antimicrobial products?
Explanation: The proposed central permission requirement aims to strengthen scrutiny of antimicrobial products. State licensing would continue, while public consultation and relevant studies serve different functions.
Frequently asked questions
1. What change is proposed for antimicrobials under the NDCT Rules, 2019?
Antimicrobials would be included in the definition of a new drug under Rule 2(1)(w)(v). The amendment is at the draft consultation stage.
2. Which authority would grant permission before a state antimicrobial manufacturing licence application?
The Central Licensing Authority would grant permission before the manufacturer applies to the concerned State Licensing Authority.
3. How long is the consultation on the draft antimicrobial amendment?
Objections and suggestions may be submitted within 30 days from the date Gazette copies containing the draft rules become publicly available.
4. Why are antimicrobial product studies relevant to the draft amendment?
Bioavailability, bioequivalence and stability assessments support scrutiny of product quality, safety and efficacy.
All sources
Original19 November 2026 · Read story


